article thumbnail

EFPIA warns EU reforms will hamstring pharma R&D

pharmaphorum

EFPIA warns EU reforms will hamstring pharma R&D Phil.Taylor Mon, 06/11/2023 - 11:46 Bookmark this

article thumbnail

How the rise of medical device use in pharma R&D is driving wearable technology in healthcare and revolutionising the medical industry

pharmaphorum

How the rise of medical device use in pharma R&D is driving wearable technology in healthcare and revolutionising the medical industry Mike.Hammerton Tue, 03/10/2023 - 08:00 Bookmark this

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The potential of AI in pharma R&D

Pharmaceutical Technology

AI in pharma R&D is one of the latest innovations helping teams apply existing knowledge to new problems. Developing a new drug is a monumental achievement — the reward of years of research and innovation.

article thumbnail

EFPIA states AI rules must “enable not hinder” pharma R&D

Drug Discovery World

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has supported the use of artificial intelligence (AI) to deliver benefit for patients, life science companies and society, in response to the EU Artificial Intelligence (AI) Act.

article thumbnail

Transforming pharma R&D with a scientist-centric approach to AI & automation

pharmaphorum

Markus Gershater looks at how automation and artificial intelligence (AI) can transform pharma R&D. As biopharmaceutical products have become increasingly complex, both in design and in regulatory requirements, we need a new way of working.

article thumbnail

Pharma R&D ROI Spikes in 2023 as ‘Breakthroughs’ Re-Energize Industry: Report

BioSpace

Pharma R&D ROI Spikes in 2023 as ‘Breakthroughs’ Re-Energize Industry: Report 4/29/2024

article thumbnail

Despite COVID-19, pharma R&D funding at all-time high: IQVIA

Outsourcing Pharma

According to the clinical research solutions firm, disruptions due to the pandemic did not stop the industry from fueling R&D at unprecedented levels.